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Although the 5-year survival rate for oesophageal 
cancer has improved from 5% to 19% over the past 
4 decades, the prognosis remains poor.[1-3] This 
is especially so in rural South Africa (SA), where 
patients present with advanced disease and therapy 
is typically directed at alleviating dysphagia, overflow of saliva, 
pulmonary aspiration and tracheo-oesophageal fistula. Over the 
past decade self-expanding metal stents (SEMS) have replaced 
surgical bypass and rigid plastic stents as the gold standard for 
mechanical palliation of this disease. Studies have shown good 
relief of dysphagia with SEMS insertion, with minimal risk.[4,5] 
In SA and in other countries, SEMS insertion is currently usually 
performed under fluoroscopic guidance, which requires access 
to a fluoroscopic suite. At Grey’s Hospital in Pietermaritzburg, 
KwaZulu-Natal Province, SA, fluoroscopy is under great demand. 
We are also faced with a significant burden of inoperable 
oesophageal cancer. In response to this high demand for a limited 
resource, we developed an alternative direct-vision approach that 
does not require fluoroscopy. This technique, first described in 
the literature in 2001,[6] has been validated with several small 
studies in equally resource-constrained environments.[7-9] This 
study at Grey’s Hospital was undertaken to describe the technique 
of stent placement using endoscopy alone and to document our 
periprocedural experience over a 5-year period (2007 - 2011). 
We hope that this alternative direct-vision approach will gain 
acceptance in the SA context, leading to more centres providing 
the service and ultimately improving patient access.
Methods
This was a retrospective analysis of all patients stented for 
oesopha geal cancer at Grey’s Hospital over the 5-year period 
2007 - 2011. Data were analysed from completed gastrointestinal 
procedure reports and included patient demographics, tumour 
length, presence of a fistula, stent size used and immediate 
complications. Other variables included the indication for 
stenting, as well as the need and indication for repeat stenting 
during the study period.
Technique
All patients gave consent for the endoscopy, dilatation and stenting 
using a standard hospital consent form. Patients were counselled 
in the appropriate language before the procedure regarding the 
dietary modifications that the stent would mandate. All stenting 
was performed in the gastrointestinal unit, under sedation using 
midazolam and fentanyl. The stents used were nitinol partially 
covered ones with a proximal release mechanism (Ultraflex; Boston 
Scientific, USA). An initial gastroscopy was performed and the 
oesophageal tumour identified. If the endoscope could be passed 
beyond the tumour, proximal and distal measurements of the 
tumour were taken. If the scope could not initially traverse the 
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Background. Self-expanding metal stents (SEMS) are widely used to palliate patients with oesophageal cancer. Placement is usually done 
under endoscopic and fluoroscopic guidance. We have developed an exclusively endoscopic technique to deploy these stents. This article 
documents the technique and periprocedural experience.
Patients and methods. All patients who had SEMS placement for oesophageal cancer at Grey’s Hospital, Pietermaritzburg, South 
Africa, over a 5-year period (2007 - 2011) were reviewed. Stenting was performed without radiological guidance using the technique 
documented in this article. At endoscopy, the oesophageal lesion was identified, dilated over a guidewire if necessary, and a partially 
covered stent was passed over the wire and positioned and deployed under direct vision. Data were captured from completed procedure 
forms and included demographics, tumour length, the presence of fistulas, stent size and immediate complications.
Results. A total of 480 SEMS were inserted, involving 453 patients, of whom 43 required repeat stenting. There were 185 female patients 
(40.8%) and 268 male patients (59.2%). The mean age was 60 years (range 38 - 101). There were 432 black patients (95.4%), 15 white patients 
(3.3%) and 6 Indian patients (1.3%). The reasons for palliative stenting were distributed as follows: age >70 years n=95 patients, tumour >8 
cm n=142, tracheo-oesophageal fistula (TOF) n=29, and unspecified n=170. One patient refused surgery, and one stent was placed for a 
post-oesophagectomy leak. Repeat stenting was for stent migration (n=15), tumour overgrowth (n=26) and a blocked stent and a stricture 
(n=1 each). Complications were recorded in six cases (1.3%): iatrogenic TOF (n=2), false tracts (n=3) and perforation (n=1). All six were 
nevertheless successfully stented. There was no periprocedural mortality.
Conclusion. The endoscopic placement technique described is a viable and safe option with a low periprocedural complication rate. It is of 
particular use in situations of restricted access to fluoroscopic guidance.
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lesion, a guidewire was passed and the lesion dilated using Savary-
Gilliard dilators up to 12 mm diameter. The scope was then 
reintroduced and tumour measurements obtained. These were 
then used to select the stent size. Optimal stent size is at least 4 cm 
longer than tumour length in order to achieve adequate proximal 
and distal coverage (of 2 cm on either side of the lesion). The 
guidewire was then inserted under vision beyond the tumour into 
the stomach, and the scope was removed.
The stent delivery system, which has markings in centimetres, 
was then passed over the guidewire and positioned using the 
proximal tumour measurement as a guide. The scope was then 
reinserted alongside the stent delivery system and the SEMS 
carefully deployed under direct vision, allowing for adjustment 
of its position. Following the procedure, the patient recovered in 
the day ward unless a complication occurred. Once the patient 
was awake, advice regarding dietary modification was repeated. 
The patient was discharged with analgesia and a diet sheet back 
to his/her referral hospital or, in the case of inpatients, back to 
the ward. Fig. 1 is a photo montage of the technique of SEMS 
deployment.
Results
A total of 506 stents were placed in 453 patients between 2007 
and 2011. Fig. 2 shows a breakdown of the numbers of procedures 
per year. There were 436 treatment-naive patients and 43 in 
whom a pre-existing SEMS had become obstructed and who 
required a salvage procedure. The mean age was 60 years, with 
the youngest patient being 38 and the oldest 101. There were 185 
female patients (40.8%) and 268 male patients (59.2%). In terms 
of racial distribution (Fig. 3), black patients overwhelmingly 
predominated. The reasons for stenting were refusal of surgery 
(n=1), post-oesophagectomy leak (n=1), and inoperable cancer in 
the remainder. Six percent of patients presented with a tracheo-
oesophageal fistula (TOF). Twenty-two percent of patients were 
older than 70 years, 32.7% had tumours that were >8 cm in 
length, and 39.4% (170/453) were deemed inoperable owing to 
comorbidities, locally advanced tumours and the presence of 
metastases. The reasons for irresectability are depicted in Fig. 4.
Repeat procedures
A total of 43 patients required a repeat procedure, 15 for stent 
migra tion, 26 for tumour overgrowth, 1 for a blocked stent 
and 1 for a stricture. Of the 436 new patients, 26 required 
restenting, giving a restent rate of 5.9%; an analysis of this subset 
is shown in Table  1. Restenting in all patients was uneventful. 
Six periprocedural complications (1.3%) occurred and included 
iatrogenic TOF (n=2), false tracts created through long tumour 
(n=3) and a single tumour perforation. All were successfully 
restented without the use of fluoroscopy, and there was no 
periprocedural mortality.
Discussion
The burden of disease due to oesophageal cancer in SA is 
large. This 5-year study reveals a significant number of patients 
with advanced oesophageal cancer who required palliation. In 
keeping with available epidemiological data, there was a male 
predominance and older patients were in the majority, although 
15.3% of the patients were <50 years of age. Oesophageal stent 
placement is usually performed under fluoroscopic guidance in 
most centres in SA. We set out to show that the purely endoscopic 
technique of SEMS placement is a safe and effective alternative 
in the palliation of malignant dysphagia. Oesophageal SEMS Fig. 1. A photo montage of the technique of deployment.
Initial gastroscopy Insertion of guidewire beyond tumour
Scope removed Dilatation performed if required 
up to 12/14 mm
Patient rescoped
Proximal and distal measurements obtained to select stent size
Guidewire reinserted
Stent delivery system passed
Positioned above proximal tumour
Scope reinserted parallel to stent
Stent slowly deployed under direct vision
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insertion forms the core of palliation in 
patients in whom curative resection is not 
possible because they are too old or frail 
or because lesions are too advanced or 
extensive. In our series, 21.9% of patients 
were >70 years old (a local cut-off for 
oesophagectomy), and the rest had locally 
advanced or metastatic disease or were 
generally in a poor cachetic condition. 
Delays in seeking medical attention, as well 
as the lack of awareness of oesophageal 
cancer in our communities, probably 
contribute significantly to the advanced 
stage of disease at presentation.
This study suggests that an exclusively 
endoscopic technique is a safe and effective 
alternative to fluroscopically guided 
placement in a resource-limited setting. 
Accurate placement of stents was confirmed 
in 100% of our patients with endoscopic 
evaluation at the time of stent deployment. 
This was true for palliating dysphagia as 
well as for stenting over malignant TOF. 
Our recorded complication rates with 
respect to perforation, need for a salvage 
procedure due to stent migration and/or 
tumour overgrowth compare favourably 
with other published series utilising both 
the fluoroscopically guided and purely 
endoscopic technique.[7,10-14] Tables 2 and 3 
compare our outcomes with those reported 
in the literature.
Currently we reserve fluoroscopic place-
ment for a select group of patients. These 
include patients in whom complete luminal 
obstruction makes safe passage of either 
the endoscope or the guidewire impossible. 
Such patients comprise about 15 - 20% of 
cases at our institution. The direct-vision 
approach allows for the majority of patients 
to be stented at a regional level and selects 
out those for whom fluoroscopy would 
be necessary. Use of routine fluoroscopy 
for all patients therefore appears to be a 
waste of a valuable resource, as well as 
contributing to an unnecessary delay in 
patient management.
Conclusion
We have developed a safe technique to 
accurately deploy SEMS under direct vision, 
thus obviating the need for fluoroscopy. 
Our study shows that the periprocedural 
complication rate is low and reaffirms that 
the exclusively endoscopic technique of 
stent insertion is a safe and effective option, 
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Fig. 3. Racial distribution of patients requiring a 
SEMS for oeosphageal cancer.
Fig. 2. SEMS deployment per year at Grey’s Hospital.
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Fig. 4. Reasons for inoperability.
Table 1. Analysis of restenting
Reason Patients, n Time from initial stent
Stent migration 11 21 days - 7 months (mean 2.1)
Proximal overgrowth 7 2 - 17 months (mean 7.3)
Distal overgrowth 6 2 - 9 months (mean 5.6)
Blocked stent 1 10 months
Stricture 1 2 months
Table 2. Comparison with other series using the direct-vison approach
N Perforation, % Mortality, % Migration, % Restent, %
Our series 436 1.4* 0 2.5 5.9
Wilkes et al., 2007[7] 98 0 0 3.1 8.9
Ben Soussan et al., 
2005[13]
33 0 3 0 18
White and 
Mungatana, 2001[14]
70 2.8 0 - 4.2
*False tract and TOF included in our series.
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especially in units with limited or no access to 
fluoroscopy. This technique is also applicable 
to patients with recurrent dysphagia (whether 
due to stent migration or tumour overgrowth) 
and to the management of malignant TOF.
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Table 3. Comparison with series using fluoroscopy
N Perforation, % Mortality, % Migration, % Restent, %
Our series 436 1.4* 0 2.5 5.9
Dobrucali and Caglar, 
2010[10]
90 0 0 4.0 11
Christie et al., 2001[11] 100 1 0 8.7 5.1
Cwiekiel et al., 1998[12] 100 1 0 3.0 7.5
*False tract and TOF included in our series.
